Results 41 to 50 of about 13,873 (197)

Assessment of a 2D electronic portal imaging devices-based dosimetry algorithm for pretreatment and in-vivo midplane dose verification

Advanced Biomedical Research, 2016
Background: The use of electronic portal imaging devices (EPIDs) is a method for the dosimetric verification of radiotherapy plans, both pretreatment and in vivo.
Ali Jomehzadeh, Parvaneh Shokrani, Mohammad Mohammadi, Alireza Amouheidari   +3 more
doaj   +1 more source

Ultra‐Radiostable Covalent Conformationally Interlocked Networks Enabling a Universal Radiometal‐Labeling Platform for Cancer Radioembolization

Advanced Science, EarlyView.
Conjugated poly(imide dioxime)‐based microspheres establish a radiometal coordination‐driven conformational interlocked network with ultra‐high radiostability. This platform enables low‐temperature, multi‐radionuclide labeling for SPECT/PET/MRI imaging and radionuclide therapy. Mechanistic insights from EXAFS and DFT reveal enhanced stability, while in
Xiao Xu, Zhenwen Zhao, Yangjie Wang, Zhigang Liu, Zhijie Liu, Xiaoling Li, Zhichen Mao, Lu Xu, Gan Lin, Gang Liu, Hongjuan Ma   +10 more
wiley   +1 more source

On the Possibility to Use the Charge Imbalance in Patients Undergoing Radiotherapy: A New Online, In Vivo, Noninvasive Dose Monitoring System

Applied Sciences, 2021
This paper describes a new real-time, in vivo, noninvasive, biasless detector system acting as a beam monitoring and relative dose measurement system.
G A Pablo Cirrone, Nino Amato, Roberto Catalano, Alessandro Di Domenico, Giacomo Cuttone, Pietro Lojacono, Alfio Mazzaglia, Fabrizio Pace, Giuseppe Pittà, Luigi Raffaele, Vincenzo Salamone, Corrado Spatola, Giada Petringa   +12 more
doaj   +1 more source

Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy

Advanced Science, EarlyView.
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier, Megane Grah Kple, Julen Ariztia, Marion Leroux, Mathieu Moreau, Michael Claron, Maxime Cheveau, Adam Laouafa, Agnieszka Kownacka, Camille Petitot, John Simonet, Alexandre M. M. Dias, Sophie Poty, Charles Truillet, Bertrand Collin, Alexandra Oudot, Franck Denat   +16 more
wiley   +1 more source

Deployment of an In Vivo Dosimetry Program with P-Type Diodes for Radiotherapy Treatments

Radiation
Background: We present the implementation of an in vivo dosimetry program that enhances treatment setups, ensuring high accuracy that is needed globally.
Miguel Felizardo, Elisabete Dias
doaj   +1 more source

In vivodosimetry: trends and prospects for brachytherapy [PDF]

The British Journal of Radiology, 2014
The error types during brachytherapy (BT) treatments and their occurrence rates are not well known. The limited knowledge is partly attributed to the lack of independent verification systems of the treatment progression in the clinical workflow routine.
Kertzscher, G, Rosenfeld, A, Beddar, S, Tanderup, K, Cygler, J E   +4 more
openaire   +4 more sources

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

Advanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert, Christophe Nguyen, Sean Edward Dunn, Magali Gary‐Bobo, Jérôme Lacombe, Justin Moser, Frédéric Zenhausern, Jean‐Olivier Durand, Frédérique Cunin   +8 more
wiley   +1 more source

Biodistribution and dosimetry of the PET radioligand [18F]CHDI-650 in mice for detection of mutant huntingtin aggregates

EJNMMI Research
Background Huntington’s disease (HD) is a rare neurodegenerative disorder caused by an expansion of the CAG trinucleotide repeat in the huntingtin gene which encodes the mutant huntingtin protein (mHTT) that is associated with HD-related ...
Jordy Akkermans, Alan Miranda, Jeroen Verhaeghe, Filipe Elvas, Franziska Zajicek, Jonathan Bard, Longbin Liu, Vinod Khetarpal, Robert Doot, Steven Staelens, Daniele Bertoglio   +10 more
doaj   +1 more source

A Validation Method for EPID In Vivo Dosimetry Algorithms

Applied Sciences, 2021
The aim of this study was to develop and apply an evaluation method for assessing the accuracy of a novel 3D EPID back-projection algorithm for in vivo dosimetry. The novel algorithm of Dosimetry Check (DC) 5.8 was evaluated. A slab phantom homogeneously
Marco Esposito, Livia Marrazzo, Eleonora Vanzi, Serenella Russo, Stefania Pallotta, Cinzia Talamonti   +5 more
doaj   +1 more source

Dual‐Target Nectin‐4/FAP Heterobivalent Probe 68Ga/177Lu‐FZ‐NF‐1 for Triple‐Negative Breast Cancer: Preclinical Theranostic Evaluation and First‐in‐Human Translation

Advanced Science, EarlyView.
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li, Li Sun, Xiaoyu Pan, Shuyi Lin, Dongliang Wang, Jianping Zhang, Fengshuang Qiu, Bin Zhu, Lingzhou Zhao, Fengsheng Zhang, Liyan Bai, Bingxin Gu, Xiaoping Xu, Shaoli Song   +13 more
wiley   +1 more source